$377 Million is the total value of CHI Advisors LLC's 24 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 71.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Buy | PROMETHEUS BIOSCIENCES INC | $100,251,367 | -1.3% | 934,135 | +1.1% | 26.61% | -1.7% |
| CGEM | Buy | CULLINAN ONCOLOGY INC | $34,264,977 | -2.1% | 3,349,460 | +1.0% | 9.10% | -2.4% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $29,499,719 | -28.4% | 2,997,939 | +7.1% | 7.83% | -28.6% |
| KROS | Buy | KEROS THERAPEUTICS INC | $11,147,219 | +7.9% | 261,059 | +21.4% | 2.96% | +7.6% |
| Buy | 2SEVENTY BIO INC | $8,721,000 | +179.3% | 855,000 | +156.6% | 2.32% | +178.2% | |
| IKNA | Buy | IKENA ONCOLOGY INC | $5,730,010 | +31.6% | 1,660,872 | +1.4% | 1.52% | +31.1% |
| Buy | RALLYBIO CORP | $4,342,701 | -9.0% | 760,543 | +4.7% | 1.15% | -9.3% | |
| New | ORCHARD THERAPEUTICS PLCspon ads new | $4,219,414 | – | 785,738 | +100.0% | 1.12% | – | |
| KDNY | New | CHINOOK THERAPEUTICS INC | $3,125,250 | – | 135,000 | +100.0% | 0.83% | – |
| New | SYROS PHARMACEUTICALS INC | $2,049,078 | – | 767,445 | +100.0% | 0.54% | – | |
| New | ENTRADA THERAPEUTICS INC | $817,423 | – | 56,374 | +100.0% | 0.22% | – | |
| RXDX | New | PROMETHEUS BIOSCIENCES INCcall | $108,125 | – | 25,000 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.